There are over twenty CHK1/2 and ten ATR inhibitors in various stages of clinical trials for many different cancer types mostly in combination with chemotherapy but also with RT and histone deacetylase inhibitors (HDACi) (96). The gene discussed is CHEK1; the disease is cancer.